**Background**
Schizophrenia is a complex, chronic mental disorder characterized by positive symptoms, such as hallucinations and delusions, as well as negative symptoms, including social withdrawal and cognitive impairment. The pathophysiology of schizophrenia is closely linked to dysregulation in the dopaminergic and serotonergic systems, particularly involving the dopamine D2-like receptors and serotonin 5-HT1A receptors. Modulating these receptors is a primary strategy for developing antipsychotic medications to alleviate psychiatric symptoms and improve patient outcomes. Consequently, the development of compounds that can precisely balance the activity of these receptors is of significant research interest. In this context, we will introduce a potent antipsychotic research tool – Bifeprunox.
**Definition**
Bifeprunox mesylate is a potent dopamine D2-like and 5-HT1A receptor partial agonist. According to the Bifeprunox description, it exhibits pKi values of 7.19 for cortex 5-HT1A and 8.83 for striatum D2, and a pEC50 of 6.37 for hippocampus 5-HT1A.
**In Vitro and In Vivo Studies**
The Bifeprunox biological activity has been extensively evaluated across various models. In terms of Bifeprunox in vitro data, the compound demonstrates a pKi of 8 at human 5-HT1A receptors, with an Emax of 70%. Regarding Bifeprunox In Vivo applications, studies have shown that administration of Bifeprunox at doses ranging from 0.001 to 2.5 mg/kg effectively reduces marble burying behavior in mice, indicating its potential antipsychotic-like effects. Furthermore, in rat models, Bifeprunox administered at doses between 4 and 250 μg/kg has been shown to influence nicotine-seeking behavior in response to drug-associated stimuli. These findings suggest that the compound’s dual action on D2 and 5-HT1A receptors may modulate both psychotic-like behaviors and addictive responses. In conclusion, Bifeprunox is a potent partial agonist of D2 and 5-HT1A receptors that serves as a valuable tool for the research of schizophrenia and related behavioral disorders.
Keywords
Bifeprunox, 350992-13-1, Dopamine Receptor, 5-HT Receptor, Serotonin Receptor, 5-hydroxytryptamine Receptor, Inhibitor, inhibitor, inhibit
References
[1] Newman-Tancredi A, et al. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol. 2005 Sep;8(3):341-56.
[2] Bruins Slot LA, et al. Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice. Behav Pharmacol. 2008 Mar;19(2):145-52.
[3] Di Clemente A, et al. Bifeprunox: a partial agonist at dopamine D2 and serotonin 1A receptors, influences nicotine-seeking behaviour in response to drug-associated stimuli in rats. Addict Biol. 2012 Mar;17(2):274-86.